Does CLONAZEPAM Cause Product packaging quantity issue? 11 Reports in FDA Database
Sharpen Your Memory & Focus Naturally
NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.
According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Product packaging quantity issue have been filed in association with CLONAZEPAM (Clonazepam). This represents 0.0% of all adverse event reports for CLONAZEPAM.
11
Reports of Product packaging quantity issue with CLONAZEPAM
0.0%
of all CLONAZEPAM reports
1
Deaths
0
Hospitalizations
How Dangerous Is Product packaging quantity issue From CLONAZEPAM?
Of the 11 reports, 1 (9.1%) resulted in death.
Is Product packaging quantity issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CLONAZEPAM. However, 11 reports have been filed with the FAERS database.
What Other Side Effects Does CLONAZEPAM Cause?
Drug ineffective (5,088)
Toxicity to various agents (4,028)
Completed suicide (3,320)
Drug abuse (3,287)
Off label use (2,590)
Anxiety (2,376)
Somnolence (2,260)
Dyspnoea (1,987)
Depression (1,838)
Insomnia (1,836)
What Other Drugs Cause Product packaging quantity issue?
LEUPROLIDE (523)
ALBUTEROL (431)
BUDESONIDE\FORMOTEROL (301)
FENTANYL (286)
BUPRENORPHINE (225)
CYCLOSPORINE (206)
ESTRADIOL (201)
BIMATOPROST (177)
RIVAROXABAN (174)
EXENATIDE (154)
Which CLONAZEPAM Alternatives Have Lower Product packaging quantity issue Risk?
CLONAZEPAM vs CLONIDINE
CLONAZEPAM vs CLOPIDOGREL
CLONAZEPAM vs CLOPIDOGREL BESILATE
CLONAZEPAM vs CLOPIDOGREL BISULFATE
CLONAZEPAM vs CLORAZEPATE